Novartis (NVS) says that the latest results from two Phase III clinical trials further the benefits of Tasigna over Glivec tablets for the treatment of Philadelphia chronic myeloid leukemia. Patients using Tasigna achieved significantly deeper molecular response versus Glivec, and the data suggests a correlation between early molecular response at three and six months and survival outcome for newly diagnosed patients.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Fri, 9:00AM)
at Zacks.com (Tue, 4:13PM)
at Investor's Business Daily (Mon, 4:49PM)
at Benzinga.com (Mon, 11:34AM)
at Investor's Business Daily (Jan 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs